3aZEVvoRtp6McXy8TuIlR6lERn067Z

Investor Relations

NYSE: NVRO

Price

121.00 -2.80 ( -2.26% ) 4:02 1/17/20 Pricing delayed 20 minutes

Volume 302,483

Recent News

See All
January 14, 2020 Nevro Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenue
Company Provides Revenue Guidance for 2020  Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its preliminary unaudited revenue for the fourth quarter and year ended December 31, 2019.  In addition, the Company is providing its worldwide revenue guidance for the full year 2020. Fourth Quarter 2019 Preliminary unaudited fourth quarter 2019 worldwide revenue is expected to be $114.4 million, compared to $107.9 million in the fourth quarter in the prior year period.  Preliminary unaudited fourth quarter 2019 U.S. revenue is expected to be $97.9 million, compared to $91.6 million in the prior year period.  Preliminary unaudited fourth quarter 2019 international revenue is expected to be $16.5 million, compared to $16.3 million in the prior year period.  Fourth quarter U.S. trial procedure growth was 17% and permanent implant procedure growth was 20%. Full Year 2019 Nevro's...
January 10, 2020 Nevro to Host Investor Briefing at North American Neuromodulation Society (NANS) 2020 Conference
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that it will host and webcast an investor briefing at the North American Neuromodulation Society (NANS 2020) in Las Vegas, NV on Saturday, January 25, 2020, beginning at 3:00 p.m. PST.  Nevro Chairman, CEO and President D. Keith Grossman will host the event and will provide a business update and answer questions from investors about the Company's latest developments. A live webcast of this event will be available on the Investors section of Nevro's website at www.nevro.com.  A webcast replay will be available approximately one hour after the live webcast ends and will be archived on the Company's website. About Nevro Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic...
December 19, 2019 Nevro to Present at the 38th Annual J.P. Morgan Healthcare Conference
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the 38 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020, beginning at approximately 9:00 a.m. (Pacific Time) at the Westin St. Francis in San Francisco, CA. A live webcast of this event will be available on the Investors section of Nevro's website at www.nevro.com. A webcast replay will be available approximately one hour after the live webcast ends and will be accessible for approximately 30 days. About Nevro Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based,...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Senza, Senza II, Senza Omnia, HF10, More, Nevro, Nevrocloud, Surpass and the Nevro, HF10, and Frequency Pairing Logos are trademarks of Nevro Corp.